rss
Br J Ophthalmol 2007;91:1341-1344 doi:10.1136/bjo.2007.124081
  • Extended report
    • Clinical science - Extended reports

Biological response modifier therapy for refractory childhood uveitis

  1. Michael Gallagher,
  2. Karina Quinones,
  3. Rene Antonio Cervantes-Castañeda,
  4. Taygan Yilmaz,
  5. C Stephen Foster
  1. Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts, USA
  1. Dr C Stephen Foster, Massachusetts Eye Research and Surgery Institute, 5 Cambridge Center, 8th Floor, Cambridge, MA 02142, USA; fosters{at}uveitis.org
  • Accepted 21 May 2007
  • Published Online First 7 June 2007

Abstract

Purpose: To evaluate the use of biological response modifiers (BRM) in the treatment of refractory childhood uveitis.

Design: Retrospective non-comparative case series of pediatric patients with uveitis treated with BRM.

Participants: 23 pediatric patients.

Methods: All children (18 years or younger) who received a BRM were assessed for visual changes, time to control inflammation, and any associated adverse side effects. Thirteen patients were treated with infliximab, five with adalimumab, and five with daclizumab. All patients had bilateral eye involvement. Diagnoses of the participants included juvenile idiopathic arthritis, keratouveitis, sarcoid panuveitis, Adamantiades–Behcets disease, and idiopathic panuveitis.

Main outcome measures: Inflammation and visual acuity.

Results: In the infliximab group 16 of 26 eyes (62%), and 10 of 13 patients (77%) demonstrated an improvement in visual acuity. Twenty of 26 eyes (77%) demonstrated an improvement in the degree of inflammation. In the adalimumab group, four of 10 eyes (40%) demonstrated an improvement in visual acuity, with five of 10 eyes (50%) demonstrating an improvement in inflammation. Four of 10 eyes (40%) in the daclizumab group demonstrated an improvement in vision with eight of 10 eyes (80%) demonstrating an improvement in inflammation.

Conclusion: BRM appear to be safe to use in children, and represent a useful therapeutic adjunctive drug group for treating recalcitrant childhood uveitides.

Footnotes

  • Competing interests: None.

  • Abbreviation:
    BRM

    Biological response modifier

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2007.124081v1
    2. 91/10/1341 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.